| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sanofi | Rilzabrutinib (PRN1008) | IgG4-related disease (IgG4-RD) | Phase 2 | Ongoing | Oral | Immunology |
| Sanofi | PRV-3279 - (PREVAIL-2) | Systemic Lupus Erythematosus (SLE) and Lupus nephritis (LN) | Phase 2a | Ongoing | Intravenous | Immunology |
| Sanofi | PRV-6527 | Crohn's disease | Phase 2a | Trial Discontinued | Oral | Gastroenterology |
| Sarepta Therapeutics Inc. | SRP-9003-301 - (EMERGENE) | Limb-girdle muscular dystrophy type 2E (LGMD2E) | BLA Filing | Ongoing | Intravenous | Genetic Disorder |
| Sarepta Therapeutics Inc. | SRP-4045 + SRP-4053 (ESSENCE) | Duchenne muscular dystrophy | Phase 3 | Data Released | Intravenous | Genetic Disorder |
| Sarepta Therapeutics Inc. | LYS-SAF302 | Mucopolysaccharidosis type IIIA (MPS IIIA) | Phase 2/3 | Ongoing | Intracerebral | Genetic Disorder |
| Sarepta Therapeutics Inc. | SRP-9001-102 | Duchenne muscular dystrophy | Phase 2 | Data Released | Intravenous | Genetic Disorder |
| Sarepta Therapeutics Inc. | SRP-5051 - (MOMENTUM) | Duchenne muscular dystrophy | Phase 2 | Data Released | Intravenous | Genetic Disorder |